In April 2019, we announced a collaboration with AstraZeneca to design and develop new treatments for disease beginning with chronic kidney disease and idiopathic pulmonary fibrosis.
By combining our AI and machine learning capabilities with AstraZeneca’s disease area expertise and large, diverse datasets, we hope to improve our understanding of complex disease biology and more quickly identify new potential drug targets.
Our biologists, chemists, engineers, informaticians and data scientists, are working together with our peers at AstraZeneca to provide new opportunities in understanding and targeting these diseases. In this video, scientists from the centre of the project chart the progress of the collaboration and share their reflections on changing the way we do drug discovery, to enable more efficient and data-driven development of new medicines.
In our opinion, partnerships aren’t forged on paper. You can’t write a partnership into being. It has to be based on a professional respect, shared ambition and a common set of values. For us this is the fusion of human expertise with technological innovation. That collision of capabilities is what will help us work together to help more people live longer, healthier lives.
Back to blog post and videos
